56 research outputs found

    Studies of azimuthal dihadron correlations in ultra-central PbPb collisions at=2.76 TeV

    Get PDF

    Observation of a peaking structure in the J/psi phi mass spectrum from B(+/-) to J/psi phi K(+/-) decays

    Get PDF

    Measurement of the production cross section for a W boson and two b jets in pp collisions at root s=7 TeV

    Get PDF
    The production cross section for a W boson and two b jets is measured using proton&#8211;proton collisions at s=7 TeV in a data sample collected with the CMS experiment at the LHC corresponding to an integrated luminosity of 5.0 fb &#8722;1 . The W+bb¯ events are selected in the W&#8594;&#956;&#957; decay mode by requiring a muon with transverse momentum pT>25 GeV and pseudorapidity |&#951;|25 GeV and |&#951;|<2.4 . The measured W+bb¯ production cross section in the fiducial region, calculated at the level of final-state particles, is &#963;(pp&#8594;W+bb¯)×B(W&#8594;&#956;&#957;)=0.53±0.05(stat.)±0.09(syst.)±0.06(theo.)±0.01(lum.) pb , in agreement with the standard model prediction. In addition, kinematic distributions of the W+bb¯ system are in agreement with the predictions of a simulation using MadGraph and pythia

    Measurement of the top-quark mass in all-jets tt events in pp collisions at root = 7 TeV

    Get PDF
    The mass of the top quark is measured using a sample of tt¯ candidate events with at least six jets in the final state. The sample is selected from data collected with the CMS detector in pp collisions at s&#8730;=7 TeV in 2011 and corresponds to an integrated luminosity of 3.54 fb&#8722;1 . The mass is reconstructed for each event employing a kinematic fit of the jets to a tt¯ hypothesis. The top-quark mass is measured to be 173.49±0.69(stat.)±1.21(syst.) GeV. A combination with previously published measurements in other decay modes by CMS yields a mass of 173.54±0.33(stat.)±0.96(syst.) GeV

    Searches for light- and heavy-flavour three-jet resonances in pp collisions at root s=8 TeV

    Get PDF

    Volumenmanagement bei chronischen Nierenerkrankungen [Volume management in chronic kidney disease]

    No full text
    Understanding the (patho-)physiology of volume regulation and osmoregulation is fundamental to guide patient advice and therapy in chronic kidney disease (CKD). Volume regulation primarily impacts the amount of sodium in the body, and it mainly affects the extracellular space, while osmoregulation primarily impacts the amount of free water, and it affects both the intra- and extracellular space. The kidneys control water and sodium homeostasis both through their sensor (e. g. tubuloglomerular feedback) and regulator systems (e. g. sodium reabsorption). Many CKD patients are advised by non-nephrologists to a high fluid intake, although they often do not require a daily intake of more than 1.5 litres. Many CKD patients are hypervolemic, and sodium restriction is of key importance in patients' effort to utilize lifestyle changes as therapeutic means. Pharmacologically, (particularly loop) diuretics are the basis of therapy, increasing sodium excretion. Recent developments shift the focus towards classes of drugs ameliorating prognosis in CKD: sodium-glucose linked transporter 2 (SGLT2) inhibitors have proven beneficial in heart and renal failure - by sodium and fluid excretion, among others; additionally, a novel mineralocorticoid receptor antagonist (MRA), finerenone, was recently shown to improve prognosis in CKD

    Comparison of two different strategies for human monocyte subsets gating within the large-scale prospective CARE FOR HOMe Study.

    No full text
    Monocytes are heterogeneous cells consisting of (at least) three subsets: classical, intermediate, and nonclassical monocytes. Correct enumeration of cell counts necessitates well-defined gating strategies, which are essentially based upon CD14 and CD16 expression. For the delineation of intermediate from nonclassical monocytes, a &quot;rectangular gating (RG) strategy&quot; and a &quot;trapezoid gating (TG) strategy&quot; have been proposed. We compared the two gating strategies in a well-defined clinical cohort of patients with chronic kidney disease (CKD). Within the ongoing CARE FOR HOMe study, monocyte subsets were reanalyzed in 416 CKD patients, who were followed 3.6&thinsp;&plusmn;&thinsp;1.6 years for the occurrence of a cardiovascular event. Gating was performed by either RG or TG. We analyzed the expression of surface markers, and compared the predictive role of cell counts of monocyte subsets, as defined by RG and TG, respectively. With both gating strategies, higher intermediate monocyte counts predicted the cardiovascular endpoint in Kaplan-Meier analyses (P&thinsp;&lt;&thinsp;0.001 with RG; P&thinsp;&lt;&thinsp;0.001 with TG). After correction for confounders, intermediate monocyte counts remained independent predictors in Cox-Regression analyses (HR&thinsp;=&thinsp;1.013 [95% CI: 1.006-1.020; P&thinsp;&lt;&thinsp;0.001] with RG; HR&thinsp;=&thinsp;1.015 [95% CI: 1.006-1.024; P&thinsp;=&thinsp;0.001] with TG). NRI was 3.9% when reclassifying patients from quartiles of intermediate monocyte counts with RG strategy toward quartiles of intermediate monocytes counts with TG strategy. In expression analysis, those monocytes which are defined as intermediate monocytes by the RG strategy and as nonclassical monocytes by the TG strategy share characteristics of both subsets. In conclusion, intermediate monocytes were independent predictors of cardiovascular outcome irrespective of the applied gating strategy. Future studies should aim to identify markers that allow for an unequivocal definition of intermediate monocytes, which may further improve their power to predict cardiovascular events

    Reprint of: MicroRNA profiling of human intermediate monocytes.

    No full text
    Crown Copyright &copy; 2016. Published by Elsevier GmbH. All rights reserved. Among the three human monocyte subsets, intermediate CD14++CD16+ monocytes have been characterized as particularly proinflammatory cells in experimental studies and as potential biomarkers of cardiovascular risk in clinical cohorts. To further substantiate the distinct role of intermediate monocytes within human monocyte heterogeneity, we assessed subset-specific expression of miRNAs as central epigenetic regulators of gene expression. We hypothesized that intermediate monocytes have a distinct miRNA profile compared to classical and non-classical monocytes. By using small RNA-seq we analyzed 662 miRNAs in the three monocyte subsets. We identified 38 miRNAs that are differentially expressed in intermediate monocytes compared to both classical and non-classical monocytes with a p value of &lt; 10-10, of which two miRNAs - miR-6087 (upregulated) and miR-150-5p (downregulated) - differed in their expression more than ten-fold. Pathway analysis of the 38 differentially expressed miRNAs linked intermediate monocytes to distinct biological processes such as gene regulation, cell differentiation, toll-like receptor signaling as well as antigen processing and presentation. Moreover, differentially expressed miRNAs were connected to those genes that we previously identified as markers of intermediate monocytes. In aggregation, we provide first genome-wide miRNA data in the context of monocyte heterogeneity, which substantiate the concept of monocyte trichotomy in human immunity. The identification of miRNAs that are specific for intermediate monocytes may allow to develop strategies, which particularly target this cell population while sparing the other two subsets
    corecore